AXL confers intrinsic resistance to osimertinib and advances the emergence of tolerant cellsHirokazu Taniguchi, Seiji Yano|Nature Communications|2019Cited by 360
Prediction of sensitivity of advanced non-small cell lung cancers to gefitinib (Iressa, ZD1839)Soji Kakiuchi, Yusuke Nakamura, Seiji Yano et al.|Human Molecular Genetics|2004Cited by 174
Transient IGF-1R inhibition combined with osimertinib eradicates AXL-low expressing EGFR mutated lung cancerRong Wang, Seiji Yano|Nature Communications|2020Cited by 112
Hepatocyte Growth Factor Reduces Susceptibility to an Irreversible Epidermal Growth Factor Receptor Inhibitor in <i>EGFR</i> -T790M Mutant Lung CancerTadaaki Yamada, Seiji Yano|Clinical Cancer Research|2009Cited by 97
High efficacy of third generation EGFR inhibitor AZD9291 in a leptomeningeal carcinomatosis model with <i>EGFR</i>-mutant lung cancer cellsShigeki Nanjo, Seiji Yano|Oncotarget|2015Cited by 58